Attacking Mycobacterium tuberculosis with designer drugs Chem 3000; Literature review Shayne Rybchinski March 26, 2009 Taken from: Davis, N., Decoding.

Slides:



Advertisements
Similar presentations
TUBERCULOSIS This is the prompt slide for the TB Therapy section.
Advertisements

The TB Alliance-Bayer Moxifloxacin Deal
Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.
Treatment of infectious diseases. Drugs used in the treatment of bacterial diseases can be grouped into categories based on their modes of action: 1.
TUBERCULOSIS Pulmonary TB.
Scott Butler Infection Innovative Medicines Group AstraZeneca R&D, Boston CPTR Workshop, 2012 Arlington, VA AZD5847 Oxazolidinone for the treatment of.
1 Marine Technology Summit November 16, Discovering and Developing New Medicines from Marine Microbes Nereus Pharmaceuticals Ken Lloyd, Ph.D. Chief.
ANTI-TUBERCULOSIS DRUGS
Multiple choice questions
Pulmonary TB. BY PROF. AZZA ELMedany Dr. Ishfaq Bukhari.
The Search for Hypermutability: Determining Frequency of Mutation in Mycobacterium smegmatis mc2155 ___________ Susan Puckett Mentors: Dr. Digby Warner,
Anti-tuberculous drugs. Mycobacteria Slow-growing bacillusDormant forms in macrophages.
Antimycobacterial drugs Tuberculosis Treatment of mycobacterial infections is complicated due: Limited information regarding antimycobacterial drug actions.
1 Antimicrobial Therapy Chemotherapy: any treatment of patient with chemicals to treat a condition. –Now word associated with cancer treatment –Our focus.
1 Antimicrobial Therapy Chemotherapy: any treatment of patient with chemicals to treat a condition. –Now word associated with cancer treatment –Our focus.
TBA-354: TBA-354 is a promising new antituberculosis nitroimidazole derivative that was tested for pharmacokinetic profile and activity against M. tuberculosis.
TUBERCULOSIS Paige Derouin. History Began infecting the first human ancestors as long as 500,000 years ago In 1882 – claimed the lives of 1 in 7 people.
TUBERCULOSIS POTENTIAL CURES THROUGH SYNTHETIC BIOLOGY.
TYPES OF ORGANIC CHEMICAL REACTIONS
Antimycobacterial drugs By Bohlooli S, PhD School of Medicine, Ardabil University of Medical Sciences.
ANTITUBERCULAR AGENTS. Tuberculosis – a chronic infectious disease caused by Mycobacterium tuberculosis Transmitted via respiratory route Organism appears.
Antibacterial Inhibitors of Cell Wall Synthesis –Very high therapeutic index Low toxicity with high effectiveness β- lactam Drugs –Inhibit peptidoglycan.
ANTITUBERCULOUS DRUGS by Dr.Mohammed Abd-Almoneim
Pulmonary TB. BY PROF. AZZA EL- MEDANY Department of Pharmacology.
PREPARED BY : DR. NEHAD JASER Tuberculosis. Tuberculosis is an infectious disease caused by the organism Mycobacterium tuberculosis. Unlike most other.
CHEMISTRY 2000 Topics of Interest #1: Blowing up Bacteria with Nitrogen Monoxide (NO)
TYPES OF ORGANIC CHEMICAL REACTIONS
Chapter 9 Aldehydes and Ketones Chemistry 20. Carbonyl group C = O Aldehydes Ketones Carboxylic acids Esters.
Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.
Chemotherapy of Tuberculosis By Prof. Azza El-Medany.
Antibiotic Resistance in Microbes A few microbes to be concerned about How some antibiotics and Antimicrobials work Resistance mechanisms Some factors.
Sydnone Chemistry and Microwave Assisted Synthesis of Sydnonyl-Substituted Imidazoles (I) Mei-Hsiu Shih Department of Chemical and Material Engineering.
Tuberculosis. Tuberculosis is an infectious disease caused by the organism Mycobacterium tuberculosis. Unlike most other bacteria, M. Tuberculosis is.
Pulmonary TB. BY PROF.  AZZA ELMedany OBJECTIVES  At the end of lecture, the students should:  Discuss the etiology of tuberculosis  Discuss the.
Asymmetric Total Synthesis of Caribenol A Author: Zhen Yang J. Am. Chem. Soc. 2010, 132, Presented by Daniel Roberts April 6 th 2014.
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology.
Treatment of Infectious Diseases. ›Drugs used to treat bacterial diseases are grouped into categories based on their modes of action Treatment of Bacterial.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
The Evaluation Of Novel Βeta-Lactam Antibiotics On Clinical Bacterial Isolates. Melvin Grimes 1, Adrienne Murphy 1,Jason Carr 2,and Debra Jackson 1, 1.
Antimycobacterial Drugs September Mycobacteria Mycobacteria are intrinsically resistant to most antibiotics. Because they grow slowly compared with.
Institute of Chemical Scienses Almaty SMART GREEN APPROACHES IN SYNTHETIC DESIGN OF BIOACTIVE POLYFUNCTIONAL AZACYCLIC SYSTEMS Institute of Chemical Scienses.
Anti-TB Agents Dr. Jeff Hobden MIP. Mycobacterium tuberculosis TB is hard to kill with antibiotics TB is hard to kill with antibiotics Slow growth Slow.
SYNTHESIS OF CHOLANE AND LANOSTANE DERIVATIVES
Dose and range (mg/kg body weight)
Cynthia Amaning Danquah UCL School of Pharmacy London, UK
Antimycobacterial drugs
CHM 708 Anti-Bacterial Drugs.
. Antitubercular Drugs.
SUSCEPTIBILITY TESTING OF MYCOBACTERIUM KANSASII STRAINS ISOLATED FROM PATIENTS BETWEEN 2000 AND 2015 IN POLAND Zofia Bakuła1, Magdalena Modrzejewska1,
1 Drug susceptible TB Limited resistance MDR-TB (Frieden, 1993) XDR-TB
MEDICAL MICROBIOLOGY ANTIBIOTICS AND CHEMOTHERAPEUTICS: AN OVERVIEW
Efficacy Study Of Potential Anti-tubercular Molecules:
By :Lecturer Nabeel Ahmed Al anbagi
Treatment of Infectious Diseases
Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.
STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.
Design & Synthesis of Mycobacterium tuberculosis TMPK Inhibitors
L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X
Pharmacology 3 Antimycobacterial drugs Lecture 12 By Prof. Dr
Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview
Investigate the Treatment of Infectious Diseases
Investigate the Treatment of Infectious Diseases
TUBERCULOSIS Pulmonary TB Drug therapy Dr. Ishfaq Dr. Aliah.
Treatment of Drug Resistant TB - Questions
Lecture 5 By Prof. dr. Mohammed Fahmy
Diversity of resistant and susceptible isolates.
Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;
Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,
Presentation transcript:

Attacking Mycobacterium tuberculosis with designer drugs Chem 3000; Literature review Shayne Rybchinski March 26, 2009 Taken from: Davis, N., Decoding Genomes Of Tuberculosis Bacteria, accessed online at on March 12, 2009http://medicineworld.org/images/news-blogs/ Taken from: Casanas, B.,Tuberculosis -- Are You at Risk?, Accessed online at on March 12, 2009

* * Taken from: Fordyce, M., What is XDR-TB? Found online at on March 12, The Resurgence of an insidious disease: 1 st line drugs: Isoniazid Rifampicin Streptomycin Ethambutol 2 nd line drugs: Amikacin Kanamycin Capreomycin Fluoroquinilone

Prado, P., Ledeit, H., Michel, S., Kock, M., Darbord, J. C., Cole, S. T., Tillequin, F., and Brodin, P. Bioorganic and Medicinal Chemistry 14 (2006) Synethesis and antimycobacterial evaluation of benzopyran analgoes. Bioorganic and Medicinal Chemistry 15 (2007) Prado, P., Janin Y. L., Saint-Joanis, B., Brodin, P., Michel, S., Koch, M., Cole, S. T., Tiellequin, F., and Bost, P. Alvey L., Prado, S., Huteau, V., Saint-Joanis, B., Michel, S., Koch, M., Cole, S. T., Tillequin, F., and Janin, Y. L., A new synthetic access to furo[3.2,-f]- chromene analogues of anantimycobacterial Bioorganic and Medicinal Chemistry 16 (2008) Benzofuro[3,2- f][1]benzopyrans: A new class of antitubercular agents

Drug Design Strategy: Inspiration from Nature Chemical Design and Synthesis of Structural Analogues with Potential Acitivity Assay anti- mycobacterium activity Test selectivity by testing toxic activity against other bacteria Assay cyto-toxicity in mammalian cells In vivo assays Determination of specific activity Usnic Acid 3,3-dimethyl-3Hbenzofuro[3,2-ƒ][1]benzopyran DBB

Fused dimethylpyran rings in nature: Benzopyran methylripariochromene A Pyranoflavanone 5-methyllupinifoliol Acridone alkaloid acrynycine

Design Targets: OH, OCO X = H, OCOCH 3 X = COH, CO, X = CH, N R = H, Me

3,3-dimethyl-3Hbenzofuro[3,2- f][1]benzopyran as a synthetic target: OH Δ 12 hrs 1.3-dichloro benzene 3,3-dimethyl- 3Hbenzofuro-[3,2ƒ]- [1]benzopyran Dimethyl- propargyl ether 3-chloro-3methyl-1-butyne + 2-hydroxydibenzofuran Prado, P., Ledeit, H., Michel, S., Kock, M., Darbord, J. C., Cole, S. T., Tillequin, F., and Brodin, P., Bioorganic and Medicinal Chemistry 14 (2006)

Pd-C H 2 Ethanol Addition across the C-C π-bond : OsO 4 NMNO 1. Acetic Anhydride 2. H 2 O NNCdM Δ 2-butanone Prado, P., Ledeit, H., Michel, S., Kock, M., Darbord, J. C., Cole, S. T., Tillequin, F., and Brodin, P., Bioorganic and Medicinal Chemistry 14 (2006)

Biological Activity; MIC 99 ( μg/ml): Isoniazid (INH) M. smegmatis M. Tuberculosis H37Ra M. Tuberculosis INH resistant E. coli >600> S. aureus >100ND--- N. asteroides Vero cells Macrophages 80>100---

Drug Design Strategy: Inspiration from Nature Chemical Design and Synthesis of Structural Analogues with Potential Acitivity Assay anti- mycobacterium activity Test selectivity by testing toxic activity against other bacteria Assay cyto-toxicity in mammalian cells In vivo assays Determination of specific activity

Replacement of the furan ring of dibenzofuran: Ethanol NaBH 3 CH 2 Cl 2, k dichloro- benzene, Δ DBU CuCl 2 ∙2H 2 O, inert atm. 1. CH 2 Cl 2 2. AlCl 3 Prado, P., Janin Y. L., Saint-Joanis, B., Brodin, P., Michel, S., Koch, M., Cole, S. T., Tiellequin, F., and Bost, P., Bioorganic and Medicinal Chemistry 15 (2007)

M. smegmatis M. Tuberculosis H37Ra Vero cells163275ND Biological Activity; MIC 95 ( μ g/ml):

Synthesis of 4-pyridal derivatives: Alvey L., Prado, S., Huteau, V., Saint-Joanis, B., Michel, S., Kock, M., Cole, S. T., Tillequin, F., and Janin, Y. L., Bioorganic and Medicinal Chemistry 16 (2008)

Δ, 12 hrs Inert atm. 1.3-dichloro benzene 2. DBU, CuCl 2 ∙2H C 4 H 5 Cl EtOH H 2 O Na 2 S 2 O 5 Synthesis of 4-pyridal analogues:

M. smegmatis > M. Tuberculosis H37Ra Biological Activity; MIC 95 ( μ g/ml):

Summary and Conclusions:  Pyridine containing DBB analogues have excellent potential to develop new TB drugs and shorten time necessary for effective treatment.  Minor perturbations in structure can have a large impact on biological activity  The design of new drugs against TB remains a global imperative

Claissen Rearrangement:

Acronycines: